Association study between fibronectin and coronary heart disease
-
Ying Zhang
Abstract
Fibronectin is a known chemoattractant for several cell types that play a role in the wound healing process, including fibroblasts, endothelial cells and macrophages. It also generates a scaffold that allows attachment of other extracellular matrix components. Large amounts of fibronectin have been detected in atherosclerotic plaques, suggesting that it may play a role in the pathogenesis of atherosclerosis. To examine the possible involvement of fibronectin in the etiology of atherosclerotic coronary heart disease, we analyzed four polymorphisms in the human fibronectin gene and determined the plasma fibronectin levels in patients with coronary heart disease (n=109) and age- and gender-matched controls (n=123) in Chinese Han people. No significant positive association was observed between these polymorphisms and coronary heart disease. The levels of circulating plasma fibronectin, however, were significantly lower in patients with coronary heart disease (mean±SD 245±87mg/L) compared with controls (354±88 mg/L) (p<0.001). The odds ratio (OR) for plasma fibronectin was 0.94 in a multivariate unconditional logistic regression model (OR=0.94, 95% CI 0.91–0.96, p<0.001). We conclude that, in our population, the four fibronectin gene polymorphisms detected are not associated with clinical coronary heart disease. Our data suggest that low circulating fibronectin levels might be a new marker of coronary heart disease.
References
1. George EL, Georges-LaBouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993; 119:1079–91.10.1242/dev.119.4.1079Search in Google Scholar PubMed
2. Kornblihtt AR, Pesce CG, Alonso CR, Cramer P, Srebrow A, Werbajh S, et al. The fibronectin gene as a model for splicing and transcription studies. FASEB J 1996; 10:248–57.10.1096/fasebj.10.2.8641558Search in Google Scholar PubMed
3. Hynes RO. Fibronectin. New York, NY: Springer Verlag, 1990.Search in Google Scholar
4. Magnusson MK, Mosher DF. Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol 1998; 18:1363–70.10.1161/01.ATV.18.9.1363Search in Google Scholar
5. Ulrich MM, Janssen AM, Daemen MJ, Rappaport L, Samuel JL, Contard F, et al. Increased expression of fibronectin isoforms after myocardial infarction in rats. J Mol Cell Cardiol 1997; 29:2533–43.10.1006/jmcc.1997.0486Search in Google Scholar PubMed
6. Tan MH, Sun ZW, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduce atherosclerosis. Blood 2004; 104:11–8.10.1182/blood-2003-09-3363Search in Google Scholar PubMed
7. Glukhova MA, Frid MG, Shekhonin BV, Vasilevskaya TD, Grunwald J, Saginati M, et al. Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 1989; 109:357–66.10.1083/jcb.109.1.357Search in Google Scholar PubMed PubMed Central
8. Thyberg J, Blomgren K, Roy J, Tran PK, Hedin U. Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J Histochem Cytochem 1997; 45:837–46.10.1177/002215549704500608Search in Google Scholar PubMed
9. Zheng F, Zhou X, Yan M, Ye SQ, Liu F. Serial analysis of gene expression from minimal amount of RNA MATERIAL. Prog Biochem Biophys 2002; 29:464–74.Search in Google Scholar
10. Avila JJ, Lympany PA, Pantelidis P, Welsh KI, Black CM, Bios RM. Fibrobnectin gene polymorphism associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999; 20:106–12.10.1165/ajrcmb.20.1.3232Search in Google Scholar PubMed
11. Nakata K, Ujike H, Sakai A, Takaki M, Imamura T, Tanaka Y, et al. Association study between the fibronectin gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 116:41–4.10.1002/ajmg.b.10796Search in Google Scholar PubMed
12. Orem C, Durmus I, Kilinc K, Baykan M, Gokce M, Orem A, et al. Plasma fibronectin level and its association with coronary artery disease and carotid intima-media thickness. Coron Artery Dis 2003; 14:219–24.10.1097/01.mca.0000066454.28270.fbSearch in Google Scholar PubMed
13. Song KS, Kim HK, Shim W, Jee SH. Plasma fibronectin levels in ischemic heart disease. Arteriosclerosis 2001; 154:449–53.10.1016/S0021-9150(00)00490-1Search in Google Scholar
14. Chen SL, Zang YM, Zhu MZ. The consumption of fibronectin content in coronary artery stenosis in dogs. Sheng Li Xue Bao 1989; 41:518–22.Search in Google Scholar
15. Malaia LT, Volkov VI, Topchii II, Dykun IaV, Shuliak LN. The content of fibronectin, fibrinogen, its degradation products and myoglobin in patients with ischemic heart disease. Ter Arkh 1990; 62:87–90.Search in Google Scholar
16. Chaialo PP, Solov'ev AV, Ena IaM, Soroka VR, Ermolin GA, Padalka MN, et al. The content of coruloplasmin, fibronectin and selenium in the blood of patients with an acute myocardial infarct. Vrach-Delo 1992; 3:15–7.Search in Google Scholar
17. Dyck RF, Orchard RC, Senger DL. The response of plasma fibronectin to acute myocardial infarction in humans. Clin Invest Med 1990; 13:107–10.Search in Google Scholar
18. Wilson CL, Schwarzbauer JE. The alternatively spliced V region contributes to the differential incorporation of plasma and cellular fibronectins into fibrin clots. J Cell Biol 1992; 119:923–33.10.1083/jcb.119.4.923Search in Google Scholar
19. Saba TM, Jaffe E. Plasma fibronectin (opsonic glycoprotein): its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am J Med 1980; 68:577–94.10.1016/0002-9343(80)90310-1Search in Google Scholar
20. Peters JH, Manuder RJ, Woolf AD, Cochrane CG, Ginsberg MH. Elevated plasma levels of ED1 cellular fibronectin in patients with vascular injury. J Lab Clin Med 1989; 113:586–97.Search in Google Scholar
21. Kanters SD, Banga JD, Algra A, Frijns RC, Beutler JJ, Fijnheer R. Plasma levels of cellular fibronectin in diabetes. Diabetes Care 2001; 24:323–7.10.2337/diacare.24.2.323Search in Google Scholar PubMed
22. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35:1671–7.10.1161/01.STR.0000131656.47979.39Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Where does the evidence come from?
- NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
- Plasma cell-free DNA as an indicator of severity of injury in burn patients
- Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
- Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
- Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
- APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
- Association study between fibronectin and coronary heart disease
- Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
- Urinary calcium excretion in severe preeclampsia and eclampsia
- In vitro re-mineralization of demineralized bone matrix in human serum
- Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
- Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
- Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
- Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
- N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
- A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
- Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
- The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
- Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
- EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
- POX-Act assay and d-ROMs test – what are the facts?
- External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
Articles in the same Issue
- Where does the evidence come from?
- NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
- Plasma cell-free DNA as an indicator of severity of injury in burn patients
- Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
- Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
- Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
- APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
- Association study between fibronectin and coronary heart disease
- Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
- Urinary calcium excretion in severe preeclampsia and eclampsia
- In vitro re-mineralization of demineralized bone matrix in human serum
- Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
- Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
- Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
- Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
- N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
- A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
- Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
- The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
- Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
- EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
- POX-Act assay and d-ROMs test – what are the facts?
- External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
